Showing 41 - 60 results of 38,872 for search '(( 50 ((greater decrease) OR (a decrease)) ) OR ( 5 ((non decrease) OR (nn decrease)) ))', query time: 0.85s Refine Results
  1. 41
  2. 42

    Transient neonatal olfactory deprivation causes a persistent decrease in the addition of CR+ PGCs. A by Yasuko Kato (122938)

    Published 2012
    “…The numbers of all three types of cells were significantly decreased by the 8<sup>th</sup> week of naris occlusion (<b>C</b>, red bars, <i>n</i> = 4) compared with the control group (<b>C</b>, blue bars, <i>n</i> = 5). …”
  3. 43
  4. 44
  5. 45

    The decrease or inhibition of Hsp90 induced REST degradation. by Raúl Orozco-Díaz (7067624)

    Published 2019
    “…<p>(A) Effect of Hsp90α ASO on cell viability. Differentiated SH-SY5Y cells were transfected with different concentrations of Hsp90α ASO. …”
  6. 46
  7. 47
  8. 48

    Probabilities of a decrease in coral cover by the years 2050 and 2099 relative to the year 2000. by Ron K. Hoeke (226302)

    Published 2011
    “…Note the 2099 “less resilient” case is the probability of a 99% or greater decrease in coral cover, other columns are for 50% or greater decrease.…”
  9. 49
  10. 50
  11. 51
  12. 52

    Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

    Published 2015
    “…<p>VCaP cells were transfected for 72h from 2.5 nM to 50 nM with siRNA TMPRSS2-ERG III, siRNA TMPRSS2-ERG IV or siRNA Control. …”
  13. 53

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  14. 54
  15. 55
  16. 56
  17. 57
  18. 58
  19. 59
  20. 60